Nephros, Inc. (NASDAQ:NEPH – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 11,100 shares, an increase of 1,750.0% from the October 15th total of 600 shares. Based on an average trading volume of 11,600 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.1% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
Separately, Benchmark reiterated a “speculative buy” rating and set a $5.00 target price on shares of Nephros in a research report on Tuesday.
View Our Latest Report on NEPH
Hedge Funds Weigh In On Nephros
Nephros Price Performance
Shares of NASDAQ:NEPH traded up $0.03 on Tuesday, reaching $1.64. The company’s stock had a trading volume of 5,461 shares, compared to its average volume of 15,139. The stock has a market capitalization of $17.29 million, a P/E ratio of -17.89 and a beta of 1.19. Nephros has a 52-week low of $1.36 and a 52-week high of $4.04. The stock’s 50-day moving average is $1.62 and its two-hundred day moving average is $1.94.
About Nephros
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Read More
- Five stocks we like better than Nephros
- What is Short Interest? How to Use It
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Why Invest in High-Yield Dividend Stocks?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- What is the Dow Jones Industrial Average (DJIA)?
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.